Cargando…

Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade

BACKGROUND: Autoinflammatory disorders are distinguished by seemingly random episodes of systemic hyperinflammation, driven in particular by IL-1. Recent pre-clinical work has shown a key role for IL-1 in epilepsy in animal models, and therapies for autoinflammation including IL-1 blockade are propo...

Descripción completa

Detalles Bibliográficos
Autores principales: DeSena, Allen D., Do, Thuy, Schulert, Grant S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807745/
https://www.ncbi.nlm.nih.gov/pubmed/29426321
http://dx.doi.org/10.1186/s12974-018-1063-2
_version_ 1783299334942490624
author DeSena, Allen D.
Do, Thuy
Schulert, Grant S.
author_facet DeSena, Allen D.
Do, Thuy
Schulert, Grant S.
author_sort DeSena, Allen D.
collection PubMed
description BACKGROUND: Autoinflammatory disorders are distinguished by seemingly random episodes of systemic hyperinflammation, driven in particular by IL-1. Recent pre-clinical work has shown a key role for IL-1 in epilepsy in animal models, and therapies for autoinflammation including IL-1 blockade are proposed for refractory epilepsy. CASE PRESENTATION: Here, we report an adolescent female with signs of persistent systemic inflammation and epilepsy unresponsive to multiple anti-epileptic drugs (AED). She was diagnosed with generalized epilepsy with a normal brain MRI and an electroencephalogram (EEG) showing occasional generalized spike and slow wave discharges. Her diagnostic evaluation showed no signs of autoimmunity or genetic causes of epilepsy or periodic fever syndromes but persistently elevated serum inflammatory markers including S100 alarmin proteins. She experienced prompt clinical response to IL-1 blockade with first anakinra and then canakinumab, with near complete resolution of clinical seizures. Additionally, she displayed marked improvements in quality of life and social/academic functioning. Baseline gene expression studies on peripheral blood mononuclear cells (PBMC) from this patient showed significantly activated gene pathways suggesting systemic immune activation, including focal adhesion, platelet activation, and Rap1 signaling, which is an upstream regulator of IL-1β production by the NLRP3 inflammasome. It also showed activation of genes that characterize inflammasome-mediated autoinflammatory disorders and no signs of interferon activation. This gene expression signature was largely extinguished after anakinra treatment. CONCLUSIONS: Together, these findings suggest that patients with epilepsy responsive to immune modulation may have distinct autoinflammatory features supporting IL-1 blockade. As such, IL-1 blockade may be highly efficacious adjunctive medication for certain refractory epilepsy syndromes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12974-018-1063-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5807745
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58077452018-02-15 Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade DeSena, Allen D. Do, Thuy Schulert, Grant S. J Neuroinflammation Case Report BACKGROUND: Autoinflammatory disorders are distinguished by seemingly random episodes of systemic hyperinflammation, driven in particular by IL-1. Recent pre-clinical work has shown a key role for IL-1 in epilepsy in animal models, and therapies for autoinflammation including IL-1 blockade are proposed for refractory epilepsy. CASE PRESENTATION: Here, we report an adolescent female with signs of persistent systemic inflammation and epilepsy unresponsive to multiple anti-epileptic drugs (AED). She was diagnosed with generalized epilepsy with a normal brain MRI and an electroencephalogram (EEG) showing occasional generalized spike and slow wave discharges. Her diagnostic evaluation showed no signs of autoimmunity or genetic causes of epilepsy or periodic fever syndromes but persistently elevated serum inflammatory markers including S100 alarmin proteins. She experienced prompt clinical response to IL-1 blockade with first anakinra and then canakinumab, with near complete resolution of clinical seizures. Additionally, she displayed marked improvements in quality of life and social/academic functioning. Baseline gene expression studies on peripheral blood mononuclear cells (PBMC) from this patient showed significantly activated gene pathways suggesting systemic immune activation, including focal adhesion, platelet activation, and Rap1 signaling, which is an upstream regulator of IL-1β production by the NLRP3 inflammasome. It also showed activation of genes that characterize inflammasome-mediated autoinflammatory disorders and no signs of interferon activation. This gene expression signature was largely extinguished after anakinra treatment. CONCLUSIONS: Together, these findings suggest that patients with epilepsy responsive to immune modulation may have distinct autoinflammatory features supporting IL-1 blockade. As such, IL-1 blockade may be highly efficacious adjunctive medication for certain refractory epilepsy syndromes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12974-018-1063-2) contains supplementary material, which is available to authorized users. BioMed Central 2018-02-09 /pmc/articles/PMC5807745/ /pubmed/29426321 http://dx.doi.org/10.1186/s12974-018-1063-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
DeSena, Allen D.
Do, Thuy
Schulert, Grant S.
Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade
title Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade
title_full Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade
title_fullStr Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade
title_full_unstemmed Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade
title_short Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade
title_sort systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807745/
https://www.ncbi.nlm.nih.gov/pubmed/29426321
http://dx.doi.org/10.1186/s12974-018-1063-2
work_keys_str_mv AT desenaallend systemicautoinflammationwithintractableepilepsymanagedwithinterleukin1blockade
AT dothuy systemicautoinflammationwithintractableepilepsymanagedwithinterleukin1blockade
AT schulertgrants systemicautoinflammationwithintractableepilepsymanagedwithinterleukin1blockade